利妥昔单抗治疗IgM单克隆自发感觉神经病  

Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy

作　　者：Goldfarb A.R. Weimer L.H. Brannagan III T.H. 李一明 

机构地区：[1]Peripheral Neuropathy Center,Dept. of Neurology and Neuroscience, Weill Med. Coll. of CornellUniv., 635 Madison Avenue, New York, NY 10022, UnitedStates Dr.

出　　处：《世界核心医学期刊文摘（神经病学分册）》2005年第8期51-51,共1页Digest of the World Core Medical Journals:Clinical Neurology

摘　　要：Rituximab, a monoclonal antibody against B-cell membrane marker CD-20, is an effective treatment for immunoglobulinM (IgM) monoclonal anti-myelin-associat ed glycoprotein(MAG) neuropathies. We report a patient with an autonomicand pain ful sensory neuropathy associated with an IgM lambda monoclonal gammopathy, resp onsive to rituximab. Treatment resulted in a decline in total IgM and improvemen t in the patient’s painful neuropathy and dysautonomia. Rituximab maybe an effe ctive and tolerable treatment for autonomic and sensory neuropathy associated wi th IgM monoclonal gammopathy.Rituximab, a monoclonal antibody against B-cell membrane marker CD-20, is an effective treatment for immunoglobulinM (IgM) monoclonal anti-myelin-associat ed glycoprotein(MAG) neuropathies. We report a patient with an autonomicand pain ful sensory neuropathy associated with an IgM lambda monoclonal gammopathy, resp onsive to rituximab. Treatment resulted in a decline in total IgM and improvemen t in the patient's painful neuropathy and dysautonomia. Rituximab maybe an effe ctive and tolerable treatment for autonomic and sensory neuropathy associated wi th IgM monoclonal gammopathy.

关 键 词：利妥昔单抗 IGM 疼痛性 族性 髓磷脂 

分 类 号：R741[医药卫生—神经病学与精神病学]